Cell line name |
SKBR3/TDR |
Accession |
CVCL_B3MN |
Resource Identification Initiative |
To cite this cell line use: SKBR3/TDR (RRID:CVCL_B3MN) |
Comments |
Population: Caucasian. Selected for resistance to: DrugBank; DB05773; Trastuzumab emtansine (T-DM1). Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175. |
Sequence variations |
- Gene deletion; HGNC; HGNC:1748; CDH1; Zygosity=Homozygous (from parent cell line).
- Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line).
|
Disease |
Breast adenocarcinoma (NCIt: C5214) |
Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
Hierarchy |
Parent: CVCL_0033 (SK-BR-3) |
Sex of cell |
Female |
Age at sampling |
43Y |
Category |
Cancer cell line |
Publications | CLPUB00650 Mohammad Ali Sabbaghi Mehrjardi; Uncovering mechanisms of acquired resistance to trastuzumab-emtansine (T-DM1) in HER2 positive breast cancer. Thesis PhD (2017); Universitat de Barcelona; Barcelona; Spain PubMed=28821558; DOI=10.1158/1078-0432.CCR-17-0696 Mohammad Ali Sabbaghi Mehrjardi, Gabriel Gil-Gomez, Cristina Guardia, Sonia Servitja, Oriol Arpi, Sara Garcia-Alonso, Silvia Menendez, Montserrat Arumi-Uria, Laia Serrano, Marta Salido, Aura Muntasell ...Show all 24 authors... , Maria Martinez-Garcia, Sandra Zazo, Cristina Chamizo, Paula Gonzalez-Alonso, Juan Madoz-Gurpide, Pilar Eroles, Joaquin Arribas, Ignasi Tusquets, Ana Lluch, Atanasio Pandiella, Federico Rojo, Ana Rovira, Joan Albanell; Show fewer authors Defective cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer. Clin. Cancer Res. 23:7006-7019(2017) |
Cross-references |
Cell line databases/resources |
cancercelllines; CVCL_B3MN
|
Encyclopedic resources |
Wikidata; Q110433236
|
Entry history |
Entry creation | 16-Dec-2021 |
Last entry update | 19-Dec-2024 |
Version number | 6 |
---|